|Description||7ACC2 did not influence the prothrombin time which, together with a good in vitro ADME profile, supports the potential of this new family of compounds to act as anticancer drugs through inhibition of lactate flux.|
|Synonyms||7ACC 2; 7ACC-2|
AZD3965 is a selective inhibitor of monocarboxylate transporter 1 (MCT1) with a binding affinity of 1.6 nM, is 6 fold selective over MCT2 and does not inhibit M...
7ACC2 did not influence the prothrombin time which, together with a good in vitro ADME profile, supports the potential of this new family of compounds to act as...
SR 13800 is a potent MCT1 inhibitor (IC50 = 0.5 nM). SR 13800 was shown to inhibit proliferation of Raji lymphoma cells in vitro and suppress lactate uptake in ...
AR-C117977 is a potent MCT1 inhibitor that inhibited the rat MLR and was more potent than cyclosporin A (CsA). AR-C117977 can reduce vimmune responses both in v...
UK-5099 is a potent inhibitor of plasma membrane monocarboxylate transporters (MCTs) and the mitochondrial pyruvate carrier (MPC). It inhibits pyruvate-dependen...
CHC is a monocarboxylic acid transport (MCT) inhibitor, displaying antitumoral and antiangiogenic activity in gliomas in vivo. It decreases glycolytic metabolis...
The hydrochloride salt form of AR-C 141990, which has been found to be a MCT1 (Monocarboxylate transporter) inhibitor.
AR-C155858 is a novel inhibitor of the monocarboxylate transporters (MCTs) MCT1 and MCT2, but exhibits no activity at MCT4. It can be used to probe MCTs’ roles ...